Paclitaxel and carboplatin for advanced breast cancer

E. A. Perez, L. C. Hartmann

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This report evaluates the activity of paclitaxel alone (Taxol; Bristol- Myers Squibb Company, Princeton, NJ), carboplatin alone, and their combination in the treatment of patients with advanced breast cancer. The preliminary safety information of this combination in other tumor types also is discussed. Finally, the overall rationale for ongoing study of the efficacy of paclitaxel and carboplatin, along with appropriate translational studies, as first-line chemotherapy in patients with metastatic breast cancer is examined. Both paclitaxel and carboplatin have well-established single- agent activity in the treatment of women with breast cancer. The tolerability of this combination, using the sequence paclitaxel followed by carboplatin infusion, already has been established in patients with lung cancer and ovarian cancer. In addition, this therapy has the novel attribute of a relative platelet-sparing effect. A phase II trial evaluating the efficacy of the paclitaxel/carboplatin combination, along with an evaluation of thrombopoietin levels and quality of life, has been initiated recently through the North Central Cancer Treatment Group. In this trial, intravenous paclitaxel 200 mg/m2 infused over 3 hours is followed by carboplatin at a calculated area under the concentration-time curve dose of 6, with cycles repeated every 21 days. Results from this trial will help document the role of the paclitaxel/carboplatin combination in the treatment of women with breast cancer.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalSeminars in Oncology
Volume23
Issue number5 SUPPL. 11
StatePublished - 1996

Fingerprint

Carboplatin
Paclitaxel
Breast Neoplasms
Thrombopoietin
Therapeutics
Ovarian Neoplasms
Lung Neoplasms
Neoplasms
Blood Platelets
Quality of Life
Safety
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Perez, E. A., & Hartmann, L. C. (1996). Paclitaxel and carboplatin for advanced breast cancer. Seminars in Oncology, 23(5 SUPPL. 11), 41-45.

Paclitaxel and carboplatin for advanced breast cancer. / Perez, E. A.; Hartmann, L. C.

In: Seminars in Oncology, Vol. 23, No. 5 SUPPL. 11, 1996, p. 41-45.

Research output: Contribution to journalArticle

Perez, EA & Hartmann, LC 1996, 'Paclitaxel and carboplatin for advanced breast cancer', Seminars in Oncology, vol. 23, no. 5 SUPPL. 11, pp. 41-45.
Perez EA, Hartmann LC. Paclitaxel and carboplatin for advanced breast cancer. Seminars in Oncology. 1996;23(5 SUPPL. 11):41-45.
Perez, E. A. ; Hartmann, L. C. / Paclitaxel and carboplatin for advanced breast cancer. In: Seminars in Oncology. 1996 ; Vol. 23, No. 5 SUPPL. 11. pp. 41-45.
@article{e6752d1cf715421d82d71a97435d1df9,
title = "Paclitaxel and carboplatin for advanced breast cancer",
abstract = "This report evaluates the activity of paclitaxel alone (Taxol; Bristol- Myers Squibb Company, Princeton, NJ), carboplatin alone, and their combination in the treatment of patients with advanced breast cancer. The preliminary safety information of this combination in other tumor types also is discussed. Finally, the overall rationale for ongoing study of the efficacy of paclitaxel and carboplatin, along with appropriate translational studies, as first-line chemotherapy in patients with metastatic breast cancer is examined. Both paclitaxel and carboplatin have well-established single- agent activity in the treatment of women with breast cancer. The tolerability of this combination, using the sequence paclitaxel followed by carboplatin infusion, already has been established in patients with lung cancer and ovarian cancer. In addition, this therapy has the novel attribute of a relative platelet-sparing effect. A phase II trial evaluating the efficacy of the paclitaxel/carboplatin combination, along with an evaluation of thrombopoietin levels and quality of life, has been initiated recently through the North Central Cancer Treatment Group. In this trial, intravenous paclitaxel 200 mg/m2 infused over 3 hours is followed by carboplatin at a calculated area under the concentration-time curve dose of 6, with cycles repeated every 21 days. Results from this trial will help document the role of the paclitaxel/carboplatin combination in the treatment of women with breast cancer.",
author = "Perez, {E. A.} and Hartmann, {L. C.}",
year = "1996",
language = "English (US)",
volume = "23",
pages = "41--45",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 11",

}

TY - JOUR

T1 - Paclitaxel and carboplatin for advanced breast cancer

AU - Perez, E. A.

AU - Hartmann, L. C.

PY - 1996

Y1 - 1996

N2 - This report evaluates the activity of paclitaxel alone (Taxol; Bristol- Myers Squibb Company, Princeton, NJ), carboplatin alone, and their combination in the treatment of patients with advanced breast cancer. The preliminary safety information of this combination in other tumor types also is discussed. Finally, the overall rationale for ongoing study of the efficacy of paclitaxel and carboplatin, along with appropriate translational studies, as first-line chemotherapy in patients with metastatic breast cancer is examined. Both paclitaxel and carboplatin have well-established single- agent activity in the treatment of women with breast cancer. The tolerability of this combination, using the sequence paclitaxel followed by carboplatin infusion, already has been established in patients with lung cancer and ovarian cancer. In addition, this therapy has the novel attribute of a relative platelet-sparing effect. A phase II trial evaluating the efficacy of the paclitaxel/carboplatin combination, along with an evaluation of thrombopoietin levels and quality of life, has been initiated recently through the North Central Cancer Treatment Group. In this trial, intravenous paclitaxel 200 mg/m2 infused over 3 hours is followed by carboplatin at a calculated area under the concentration-time curve dose of 6, with cycles repeated every 21 days. Results from this trial will help document the role of the paclitaxel/carboplatin combination in the treatment of women with breast cancer.

AB - This report evaluates the activity of paclitaxel alone (Taxol; Bristol- Myers Squibb Company, Princeton, NJ), carboplatin alone, and their combination in the treatment of patients with advanced breast cancer. The preliminary safety information of this combination in other tumor types also is discussed. Finally, the overall rationale for ongoing study of the efficacy of paclitaxel and carboplatin, along with appropriate translational studies, as first-line chemotherapy in patients with metastatic breast cancer is examined. Both paclitaxel and carboplatin have well-established single- agent activity in the treatment of women with breast cancer. The tolerability of this combination, using the sequence paclitaxel followed by carboplatin infusion, already has been established in patients with lung cancer and ovarian cancer. In addition, this therapy has the novel attribute of a relative platelet-sparing effect. A phase II trial evaluating the efficacy of the paclitaxel/carboplatin combination, along with an evaluation of thrombopoietin levels and quality of life, has been initiated recently through the North Central Cancer Treatment Group. In this trial, intravenous paclitaxel 200 mg/m2 infused over 3 hours is followed by carboplatin at a calculated area under the concentration-time curve dose of 6, with cycles repeated every 21 days. Results from this trial will help document the role of the paclitaxel/carboplatin combination in the treatment of women with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0029847137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029847137&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 41

EP - 45

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 11

ER -